trientine has been researched along with Liver Neoplasms in 4 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We administered trientine hydrochloride, a drug used in the treatment of Wilson's disease, to patients with hepatocellular carcinoma after radical treatment with percutaneous ethanol injection or radiofrequency ablation, and examined its effect on the reduction of liver-tissue copper content." | 9.11 | Metal contents of liver parenchyma after percutaneous ethanol injection or radiofrequency ablation in patients with hepatocellular carcinoma before and after trientine hydrochloride therapy. ( Ebara, M; Fukuda, H; Kondo, F; Okabe, S; Saisho, H; Sugiura, N; Yoshikawa, M; Yukawa, M, 2004) |
| " We examined the antiangiogenic effect against hepatocellular carcinoma (HCC) of the copper chelator trientine, especially focusing on the relationship between copper and interleukin-8 (IL-8), a potent angiogenic factor produced by hepatoma cells." | 7.71 | The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. ( Kagawa, K; Katagishi, T; Kimura, H; Mitsumoto, Y; Moriguchi, M; Nakajima, T; Okanoue, T; Takashima, H; Watanabe, T, 2002) |
| " We examined the effects of trientine on the spontaneous development of hepatitis and hepatic tumors, by its short-term and long-term administration to Long-Evans cinnamon (LEC) rats with an accumulation of copper in the liver, as animal models of Wilson's disease." | 5.29 | Inhibition of hereditary hepatitis and liver tumor development in Long-Evans cinnamon rats by the copper-chelating agent trientine dihydrochloride. ( Maeda, M; Mori, M; Nagao, M; Sone, K; Sugimura, T; Takeichi, N; Wakabayashi, K, 1996) |
| "We administered trientine hydrochloride, a drug used in the treatment of Wilson's disease, to patients with hepatocellular carcinoma after radical treatment with percutaneous ethanol injection or radiofrequency ablation, and examined its effect on the reduction of liver-tissue copper content." | 5.11 | Metal contents of liver parenchyma after percutaneous ethanol injection or radiofrequency ablation in patients with hepatocellular carcinoma before and after trientine hydrochloride therapy. ( Ebara, M; Fukuda, H; Kondo, F; Okabe, S; Saisho, H; Sugiura, N; Yoshikawa, M; Yukawa, M, 2004) |
| " We examined the antiangiogenic effect against hepatocellular carcinoma (HCC) of the copper chelator trientine, especially focusing on the relationship between copper and interleukin-8 (IL-8), a potent angiogenic factor produced by hepatoma cells." | 3.71 | The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. ( Kagawa, K; Katagishi, T; Kimura, H; Mitsumoto, Y; Moriguchi, M; Nakajima, T; Okanoue, T; Takashima, H; Watanabe, T, 2002) |
| " We examined the effects of trientine on the spontaneous development of hepatitis and hepatic tumors, by its short-term and long-term administration to Long-Evans cinnamon (LEC) rats with an accumulation of copper in the liver, as animal models of Wilson's disease." | 1.29 | Inhibition of hereditary hepatitis and liver tumor development in Long-Evans cinnamon rats by the copper-chelating agent trientine dihydrochloride. ( Maeda, M; Mori, M; Nagao, M; Sone, K; Sugimura, T; Takeichi, N; Wakabayashi, K, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harada, M | 1 |
| Honma, Y | 1 |
| Yoshizumi, T | 1 |
| Kumamoto, K | 1 |
| Oe, S | 1 |
| Harada, N | 1 |
| Tanimoto, A | 1 |
| Yabuki, K | 1 |
| Karasuyama, T | 1 |
| Yoneda, A | 1 |
| Shibata, M | 1 |
| Moriguchi, M | 1 |
| Nakajima, T | 1 |
| Kimura, H | 1 |
| Watanabe, T | 1 |
| Takashima, H | 1 |
| Mitsumoto, Y | 1 |
| Katagishi, T | 1 |
| Okanoue, T | 1 |
| Kagawa, K | 1 |
| Fukuda, H | 1 |
| Ebara, M | 1 |
| Okabe, S | 1 |
| Yoshikawa, M | 1 |
| Sugiura, N | 1 |
| Saisho, H | 1 |
| Kondo, F | 1 |
| Yukawa, M | 1 |
| Sone, K | 1 |
| Maeda, M | 1 |
| Wakabayashi, K | 1 |
| Takeichi, N | 1 |
| Mori, M | 1 |
| Sugimura, T | 1 |
| Nagao, M | 1 |
1 trial available for trientine and Liver Neoplasms
| Article | Year |
|---|---|
Metal contents of liver parenchyma after percutaneous ethanol injection or radiofrequency ablation in patients with hepatocellular carcinoma before and after trientine hydrochloride therapy.
Topics: Aged; Carcinoma, Hepatocellular; Chelating Agents; Combined Modality Therapy; Copper; Ethanol; Femal | 2004 |
3 other studies available for trientine and Liver Neoplasms
| Article | Year |
|---|---|
Idiopathic copper toxicosis: is abnormal copper metabolism a primary cause of this disease?
Topics: Carcinoma, Hepatocellular; Ceruloplasmin; Chelating Agents; Chemical and Drug Induced Liver Injury; | 2020 |
The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Chelating Age | 2002 |
Inhibition of hereditary hepatitis and liver tumor development in Long-Evans cinnamon rats by the copper-chelating agent trientine dihydrochloride.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Chelating Agents; Copper; Hepatitis; Liv | 1996 |